Every figure below is transcribed from published literature (peptideprotocolportal.com, compiled 2026-09-29). None of it is a recommendation, a protocol, or a target, and none of it was written here. Whether any of it applies to a person is a question for a licensed clinician — who this is for explains why.
Cautions
The source records no specific caution for Larazotide (AT-1001). That is a fact about the document rather than about the compound: it means this table does not state one, not that none exists. The general exclusions on who this is for apply to everything in this reference.
As reported
The single row the source carries for this compound.
| Vial | Dose | Frequency | Route |
|---|---|---|---|
| 5mg | 0.5-1mg | 1-2x/day before meals | Oral (submucosal) |
The source's own notes
Reproduced in full, including the parts that are description rather than caution. Trimming this column for layout would remove its harm-reduction payload.
Tight junction regulator. Celiac disease, leaky gut, intestinal permeability. Swish and hold 60-90 sec. 6-8 week cycles. Synergistic with BPC-157 and KPV
Before anything else
A compound's paperwork is the part you can actually verify. Reading a Certificate of Analysis and what a COA cannot tell you cover both halves of that, and inspecting a vial on arrival covers what to check before a vial is opened at all.